Literature DB >> 22183937

Obstructive sleep apnea is associated with fatigue in multiple sclerosis.

M Kaminska1, R J Kimoff, A Benedetti, A Robinson, A Bar-Or, Y Lapierre, K Schwartzman, D A Trojan.   

Abstract

BACKGROUND: Multiple sclerosis (MS) patients often suffer from fatigue.
OBJECTIVE: We evaluated the relationship of obstructive sleep apnea (OSA) to fatigue and sleepiness in MS patients.
METHODS: Ambulatory MS patients without known sleep disorders and healthy controls underwent diagnostic polysomnography and a multiple sleep latency test (objective sleepiness measure). Fatigue was measured with the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI), and subjective sleepiness by Epworth Sleepiness Scale. Covariates included age, sex, body mass index, Expanded Disability Status Scale (EDSS), depression, pain, nocturia, restless legs syndrome, and medication.
RESULTS: OSA (apnea-hypopnea index ≥ 15) was found in 36 of 62 MS subjects and 15 of 32 controls. After adjusting for confounders, severe fatigue (FSS ≥ 5) and MFI-mental fatigue (>group median) were associated with OSA and respiratory-related arousals in MS, but not control subjects. Subjective and objective sleepiness were not related to OSA in either group. In a multivariate model, variables independently associated with severe fatigue in MS were severe OSA [OR 17.33, 95% CI 2.53-199.84], EDSS [OR 1.88, 95% CI 1.21-3.25], and immunomodulating treatment [OR 0.14, 95% CI 0.023-0.65].
CONCLUSIONS: OSA was frequent in MS and was associated with fatigue but not sleepiness, independent of MS-related disability and other covariates.

Entities:  

Mesh:

Year:  2011        PMID: 22183937     DOI: 10.1177/1352458511432328

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  49 in total

1.  Sleep disorders in patients with multiple sclerosis in China.

Authors:  Shengli Ma; Xue Rui; Peiyi Qi; Gangqiong Liu; Jing Yang
Journal:  Sleep Breath       Date:  2016-10-11       Impact factor: 2.816

Review 2.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

3.  Association between OSA and severe fatigue in patients with multiple sclerosis (MS).

Authors:  Marta Kaminska; Daria A Trojan; R John Kimoff
Journal:  J Clin Sleep Med       Date:  2014-06-15       Impact factor: 4.062

4.  Obstructive sleep apnea is an under-recognized and consequential morbidity in multiple sclerosis.

Authors:  Tiffany J Braley; Benjamin M Segal; Ronald D Chervin
Journal:  J Clin Sleep Med       Date:  2014-06-15       Impact factor: 4.062

5.  The underdiagnosis of sleep disorders in patients with multiple sclerosis.

Authors:  Steven D Brass; Chin-Shang Li; Sanford Auerbach
Journal:  J Clin Sleep Med       Date:  2014-09-15       Impact factor: 4.062

6.  Central sleep apnea in multiple sclerosis: a pilot study.

Authors:  Michael Lin; Arun V Krishnan; Danny J Eckert
Journal:  Sleep Breath       Date:  2016-12-14       Impact factor: 2.816

7.  NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.

Authors:  Richard A Sater; Mark Gudesblatt; Kiren Kresa-Reahl; David W Brandes; Pamela Sater
Journal:  Int J MS Care       Date:  2016 Jul-Aug

Review 8.  Sleep Abnormalities in Multiple Sclerosis.

Authors:  Giorgos K Sakkas; Christoforos D Giannaki; Christina Karatzaferi; Mauro Manconi
Journal:  Curr Treat Options Neurol       Date:  2019-01-31       Impact factor: 3.598

Review 9.  [Therapy of fatigue in multiple sclerosis : A treatment algorithm].

Authors:  C Veauthier; F Paul
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

Review 10.  Sleep Disorders in Multiple Sclerosis.

Authors:  Tiffany J Braley; Eilis Ann Boudreau
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.